PT-112
Phase 2Small molecule
PT-112 is one of 42 small molecule programs targeting Thymic Epithelial Tumor. It is currently in Phase 2.
2
Indications
7
Total Trials
2
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
311 competitors in Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Taxol
TevaPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Tecentriq
RochePhase 2
Beyfortus
BeiGenePhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Alimta
SShawn Eagle
Phase 2
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 2
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 2
Recentin
NNational Cancer Institute (NCI)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors3 trials
Non-Small Cell Lung Cancer1 trial
An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study
Unknown status·SSciClone Pharmaceuticals International (Cayman) Development Limited·Phase 1/2·NCT02884479·75 enrolled
Multiple Myeloma1 trial
Hepatocellular Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PT-112. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- PPromontory Therapeutics Inc.